$GRTX News

Galera Therapeutics Q1 EPS $(0.01), Same YoY

Galera Therapeutics Q3 EPS $(0.01) Up From $(0.10) YoY

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

Galera Therapeutics Q1 EPS $(0.01) Up From $(0.08) YoY

Galera Therapeutics completes acquisition of Nova Pharmaceuticals

UroGen Pharma CFO Don Kim departs, Chris Degnan succeeds

Galera Announces Board Approval of Complete Liquidation and Dissolution

Galera Therapeutics Announces Wind-Up and Special Stockholder Meeting

Galera Therapeutics reports Q2 EPS (7c) vs. (48c) last year

Galera Therapeutics to reduce workforce to three employees

Galera Therapeutics announces board approval of liquidation, dissolution

GRTX Stock Earnings: Galera Therapeutics Reported Results for Q2 2024

Galera Therapeutics Settles Clinical Trial Dispute Lawsuit

Galera Therapeutics Restructures Leadership and Cuts Costs

Why Galera Therapeutics (GRTX) Stock Is Nosediving

Galera Therapeutics shares are trading lower after the company announced it will be delisted by Nasdaq.

Galera Therapeutics To Be Delisted By Nasdaq, Trading Suspended June 4; Shares Expected To Trade On OTC Under Symbol "GRTX"

12 Health Care Stocks Moving In Wednesday's After-Market Session

Piper Sandler Initiates Coverage On Galera Therapeutics with Overweight Rating, Announces Price Target of $6